Press Releases

Profacgen Provides Pharmacophore Modeling for Drug Design

Creative Biostructure Updated Its Membrane Protein Service

Lifeasible Updated Its Physical Purity Testing Service for Seed Testing

Matexcel Updated Its Customized Polymerization Service

Customized Biodegradable Polymers Are Available at CD Bioparticles

Empowered by leading technology and years of experience in drug delivery, CD Bioparticles now integrate various kinds of biodegradable polymers into its all-inclusive array of products covering lipids, liposomes, biopolymers and synthetic polymers.

bioBoaVista manufactures customised media for COVID nasal diagnostic tests using the Flexicon PF7

bioBoaVista has developed a viral transport medium for more efficient nasal tests for the diagnosis of COVID-19 using the Flexicon PF7 bench top filling machine from Watson-Marlow Fluid Technology Group.

COVID-19 SCREENING IN IVF CLINICS: SAFETY IS THE PRIORITY

Inconsistencies in guidance for IVF clinics cause confusion, says Bourn Hall’s Medical Director

Creative Bioarray Unveils Comprehensive Histology Services to Accelerate The Projetcs in Biolinical Research

Shimmer Named 2020 Citeline Award Finalist for Its Verisense™ Continuous Monitoring Platform for Clinical Trials; Co-founding Open Wearables Initiative

Shimmer’s Verisense platform reliably captures accurate and complete biometric data, while placing minimum burden on clinical trial sponsors, sites and participants. The Open Wearables Initiative (www.OWEAR.org) is an industry collaboration designed to promote the effective use of high-quality, sensor-generated measures of health in clinical research through the open sharing of algorithms and datasets.

eClinical Solutions Teams with Karyopharm for COVID-19 Treatment Trial

Selinexor study is the first exploration of an XPO1 inhibitor in patients with severe viral infections

ERT Continues to Drive Innovation in Virtualization for Respiratory Clinical Trials

Partnership with Inofab Health keeps respiratory trials on track and ensures patient safety during and after COVID-19

Panthera and Rutherford Health launch innovative oncology clinical trial network

Panthera and Rutherford Health launch innovative oncology clinical trial network with expertise across more than 40 types of cancer; access to patients from more than 170 referring oncologists; and state-of-the-art cancer treatment and diagnostic centres.

Sharp Clinical Launches Direct-to-Patient Service with New Partnerships

Sharp Clinical Services, part of UDG Healthcare and a leading provider of global clinical supply services, has signed a central pharmacy partnership deal and developed a holistic patient support programme with its sister company, Ashfield.

Florence Healthcare Names Melinda Rodriguez Winner of The Florence Effect Initiative

Florence Healthcare, the leading platform for remote-enabled electronic document workflow management in clinical trials, is proud to name Melinda Rodriguez, Director of Regulatory Services at Elligo Health Research, as the winner of The Florence Effect initiative.

The University of Aberdeen chooses BridgeHead’s ICA

CORONAVIRUS TEST WINS FUNDING FROM INNOVATE UK

Sugar based technology offers diagnosis on the spot in under 15 minutes

ERT Acquires APDM Wearable Technologies to Reinvent Endpoint Measurement in Clinical Trials

Combining APDM’s precision motion wearables and digital biomarkers with ERT’s eClinical Suite revolutionizes clinical trials

ArisGlobal Announces the All-New LifeSphere® Regulatory Platform, Bringing Game-Changing Efficiency to Regulatory Information Management

The new LifeSphere Regulatory platform includes LifeSphere® RIMS, a complete solution for managing all core regulatory processes, and LifeSphere® Publishing, a submissions management system that enables life science organizations to easily compile, publish, and validate regulatory submissions with full support for all major global eCTD requirements.

NFlection Therapeutics Launches with $20M Series A Funding to Advance Lead Program in Neurofibromatosis

NFX-179 Gel is different from other treatments for neurofibromatosis, both FDA approved and in the pipeline, and this funding and new development highlights the importance of the “soft drug” approach as well as how the $20 M Series A funding from venBio and F-Prime Capital will be used to advance NFlection’s lead program in developing therapies for rare disorders known as RASopathies, including NF1.

AI & Medicine Launches AI-Powered Drug Discovery Platform for the Science Community

On April 21, 2020, AI & Medicine proudly announced that it has successfully developed a unique artificial intelligence (AI) drug discovery platform, offering drug research and development solutions for medical institutions and pharmaceutical enterprises worldwide.